The selectivity of certain benzophenones and their carbonyl N-analogues was investigated towards the human GSTP1-1 allozymes A, B and C involved in MDR. The allozymes were purified from extracts derived from E. coli harbouring the plasmids pEXP5-CT/TOPO-TAhGSTP1*A, pOXO4-hGSTP1*B or pOXO4-hGSTP1*C. Compound screening with each allozyme activity indicated three compounds with appreciable inhibitory potencies, 12 and 13 with P1-1A 62% and 67%, 11 and 12 with P1-1C 51% and 70%, whereas that of 15 fell behind with P1-1B (41%). These findings were confirmed by IC 50 values (74-125 lM). Enzyme inhibition kinetics, aided by molecular modelling and docking, revealed that there is competition with the substrate CDNB for the same binding site on the allozyme (K i(13/ A) = 63.6 AE 3.0 lM, K i(15/B) = 198.6 AE 14.3 lM, and K i(11/ C) = 16.5 AE 2.7 lM). These data were brought into context by an in silico structural comparative analysis of the targeted proteins. Although the screened compounds showed moderate inhibitory potency against hGSTP1-1, remarkably, some of them demonstrated absolute isoenzyme and/or allozyme selectivity.
Benzophenones, along with bioflavonoids, coumarins and xanthones, constitute a major class of compounds exhibiting multiple biological activities (1) . o-Hydroxybenzophenone derivatives, in particular, are ubiquitous in nature but also synthetically obtained compounds, for example certain combretastatins and phenstatins (2) . Our recently reported interest in utilizing the reactivity profile of xanthone (3) in synthesis (4, 5) , as well as its inhibitory potential towards the medically important human isoenzyme glutathione transferase A1-1 (hGSTA1-1) (6), prompted us to investigate xanthone ring-opened analogues, substituted 2,2 0 -o-dihydroxybenzophenones, towards hGSTA1-1 (7), taking advantage of their structure similarities, in pursuit of promising inhibitor lead structures against this enzyme, involved in multiple drug resistance (MDR). To that end, GSTs (EC 2.5.1.18) are cell-detoxifying agents, for they catalyse the coupling of glutathione (GSH) to hydrophobic xenobiotic and endogenous compounds, rendering them hydrophilic and, thus, facilitating their metabolic processing and eventual secretion from the cell (8) . Based on the same detoxification mechanisms, cancer cells often acquire resistance by overexpressing GSTs (9) , hampering the effectiveness of certain chemotherapeutic drugs. In particular, GSTs of the p class are the most studied isoenzymes in human cancer. Their expression levels vary with tumour type and stage, hence affecting the effectiveness of anticancer drugs, for example thiotepa and chlorambucil (10) (11) (12) . Therefore, certain GST-recognizing drugs and prodrugs have been suggested to overcome MDR attributed to GST overexpression (13) (14) (15) . For example, the prodrug TLK286 (Telcyta) is activated by hGSTP1-1, after being triggered by Tyr7 located in the active region of the isoenzyme (16) . As tumour-protective phenomena may vary by patient GST isoenzyme/allozyme profiles, we thought to study dihydroxybenzophenones and their carbonyl N-analogues as inhibitors discriminating not only between A1-1 and P1-1 hGST isoenzymes but also between hGSTP1-1 allozymes A, B and C, involved in MDR (17) .
Materials and Methods
Expression and purification of hGSTP1-1 allozymes The expression was based on a published method with modifications (18) , whereas the enzyme purification procedures were developed in our laboratory (Appendix S1).
Routine enzyme assay for determining GST activity Determination of GST activity was performed by monitoring the formation of the conjugate between CDNB and GSH at 340 nm (e = 9600 L/mole/cm) at 6.5 and 25°C. One unit of enzyme activity is defined as the amount of enzyme that produces 1.0 lmole of product per minute under the assay conditions (7).
Compound screening as inhibitors for hGSTP1-1 allozymes ('cherry picking') 'Cherry picking' was performed by introducing the ingredients in the following order (1 mL final assay volume): potassium phosphate buffer (approx. 100 mM final, pH 6.5), CDNB (20 lL from 50 mM stock solution prepared in ethanol; 1.0 mM final), test compound (20 lL from 5 mM stock solution in DMSO; 0.1 mM final) and enzyme (typically, 80 lL from hGSTP1A producing 0.0370 DΑ 340 /min, 50 lL from hGSTP1B producing 0.0491 DΑ 340 /min and 35 lL from hGSTP1B (previously diluted with buffer, 1:10 v/v) producing 0.0502 DΑ 340 /min). After mixing, the reaction started by adding GSH (20 lL from 125 mM stock prepared in water; 2.5 mM final) and continued for 1 min at 25°C. The observed rate was used to calculate the remaining activity (%), taking as 100% initial activity value the rate observed, after replacing the test compound by an equal volume of DMSO which, in all assays, was maintained at a 2% v/v final concentration.
Determination of IC 50 values for inhibitors selected from 'cherry picking' Initial velocities for the GST-catalysed reaction with CDNB (1 mM) and GSH (2.5 mM) as substrates were measured at 25°C, in the presence of various concentrations of the inhibitors selected from 'cherry picking', using the same assay conditions (see previous paragraph). Different inhibitor quantities, in 20 lL DMSO, were introduced in the assay mixture. The observed rate was used to calculate the remaining activity (%), taking as 100% initial activity value the observed rate, after replacing the inhibitor by an equal volume of DMSO (20 lL). The IC 50 values were determined from a graph depicting remaining GST activity (%) against inhibitor concentration.
Kinetic analysis of inhibitors selected from 'cherry picking' Initial velocities for the GST-catalysed reaction with CDNB as variable substrate were determined in reaction mixtures of a total volume of 1 mL (25°C) containing potassium phosphate buffer (100 mM, pH 6.5), 2.5 mM GSH and different concentrations of CDNB (60-2100 lM with hGSTP1A, 75-2100 lM with hGSTP1B and 37.5-2100 lM with hGSTP1C) in the absence and presence of inhibitor 13 (0, 25 and 50 lM with hGSTP1A) or inhibitor 15 (0, 40, 80 and 100 lM with hGSTP1B) or inhibitor 11 (0, 15, 30, 70 and 100 lM with hGSTP1C). Initial velocities for the hGSTA1-1-catalysed reaction with GSH as variable substrate were determined in reaction mixtures of a total volume of 1 mL (25°C) containing potassium phosphate buffer (100 mM, pH 6.5), 1 mM CDNB and different concentrations of GSH (45-2500 lM) in the absence and presence of inhibitor 11 (0, 15, 30 and 60 lM).
Modelling and docking: the in silico structures of hGSTPs and docking of the 2,2 0 -dihydroxybenzophenones and their carbonyl Nanalogues The structure of hGSTP1-1 (variant or allozyme A) in complex with ethacrynic acid and its glutathione conjugate was downloaded from the Protein Data Bank (PDB code 11GS) and prepared with the Protein Preparation Wizard (19) in Maestro (Schrodinger, LLC, New York, NY, USA). Two further variants (allozymes B and C), according to their amino acid substitutions in positions 104 and 113, were constructed, using the X-ray structure of allozyme B (PDB code 1PGT) and a constructed model for the mutant of the external surface mutation Ala113Val, defining the optimal rotamers of the respected side chains using 12 nseconds molecular dynamics on DESMOND 3.6 (20) . Rotamers were displayed with PyMOL ( Figure S1 ). A docking grid, including the tripeptide substrate glutathione, was set up centred on ethacrynic acid (Table S1 ). OMEGA 2.5.1.4 (OpenEye Scientific Software) (21) was used to generate molecular conformations of the synthetic analogues. Potentially active compounds with a similar shape to parental compounds were identified by ROCS 3.2.0.4 (22) fast shape comparison application. The synthetic analogues were docked flexibly using Glide SP (23, 24) (Table  S1 ). Docking results (Table S2a ,b,c) were both visually inspected and quantitatively evaluated based on a docking score. Docking results were checked for positional stability using postdocking molecular dynamics with Desmond 3.6 (Table S3 ). All figures depicting 3D models were created using PYMOL, version 1.7.4 (Schrodinger, LLC).
Results and Discussion
The hGSTP1 allozymes were purified on a GSH-affinity chromatography column (enzyme desorption with 10 mM GSH), leading to enzyme preparations of good purification characteristics and overall protocol performance (Table S4) .
Compound screening and selection of inhibitors for hGSTP1-1 To reveal the enzyme inhibitory potency of the 2,2 0 -dihydroxybenzophenones and their carbonyl N-analogues, all compounds were subjected to screening against the three allozymes, hGSTP1A, hGSTP1B and hGSTP1C. In designing the screening enzyme assay protocol against hGSTP1-1, the concentration of 100 lM was chosen. This choice was dictated by preliminary experiments run at concentrations in the range 1-30 lM, as suggested in the literature (7, 25) , showing the compounds not to be as effective inhibitors with the P1-1 isoenzyme as they were with A1-1 (7). A more crucial factor to be decided has been the substrate concentration, CDNB, in the enzyme inhibition assay for 'cherry picking' and IC 50 determinations. Having initially considered the known Michaelis constant for the CDNBhGSTP1-1 couple (K m = 0.98 AE 0.06 mM) (17), we performed inhibition assays at [CDNB] = 1 mM, fulfilling the so-called balanced assay conditions, that is [CDNB] % K m , acknowledged in the literature as the optimum choice (6, 7, 25) . From the screening data obtained (Table 1, Figure S2) , one distinguishes three groups of inhibitory potency against the hGSTP1 allozymes (Table S5) : <20% (low inhibition), 20-40% (medium inhibition) and 50-80% (high inhibition), using 100 lM of compound. A forth group of 'very high' inhibition (>80%) is applicable only to isoenzyme hGSTA1-1, when using only 25 lM of compound (Table S5 ). The compounds with the strongest inhibition potency for hGSTP1-1 were further studied to determine their IC 50 values from concentration-response curves ( Figure 1 , Table S6 ). Predictably, compounds with higher % inhibition potency exhibited lower IC 50 values. It appears that the compounds are not, overall, as effective for hGSTP1-1 inhibition, as for hGSTA1-1 (Table 1) . However, it is most interesting that some of them exhibited a clear preference with respect to a particular isoenzyme. For example, 6, 8, 9 and 15, although weak inhibitors for the P1-1A allozyme at 100 lM (Table 1 ; % 41%, 0%, 0% and 24%, respectively), are rather potent for isoenzyme A1-1 at only 25 lM (% 86%, 88%, 59% and 96%, respectively). Even a more interesting behaviour is shown by certain compounds that demonstrated absolute selectivity for specific isoenzymes and/or allozymes. For example, 6 and 7, the 5-mono-and 5,5
0 -di-phenyl-substituted benzophenones, show absolute selectivity for A1-1 over the P1-1B allozyme (Table 1 ; % 86% and 34% versus 0%, respectively), whereas additional absolute selectivity for A1-1 is shown by 7 over the P1-1C allozyme. In practice, 6 is also selective for A1-1 over the P1-1B allozyme (% 86% versus 3.0%, respectively). Likewise, 8 and 9, the 5-mono-and 5,5 0 -di-brominated benzophenones, show absolute selectivity for A1-1 over P1-1A (Table 1 ; % 88% and 59% versus 0%, respectively), whereas additional absolute selectivity for A1-1 is shown by 8 over the P1-1B allozyme and by 9 over the P1-1C allozyme. Even 15 can practically be regarded as one of absolute selectivity with hGSTA1-1 (%96% inhibition) over hGSTP1-1C (14% inhibition), as the latter is diminished at 25 lM. On the other hand, 11, 12 and 13 show numerically comparable inhibitory potencies with A1-1 and P1-1 (Table 1 ; 11: 52% versus 31%; 12: 68% versus 67%; 13: 87% versus 62%), thus being adequate inhibitors for both isoenzymes, nevertheless still more potent with hGSTA1-1. On the basis of these observations, we went on to investigate further the modality of interaction between the most potent inhibitors and the target hGSTP1 allozymes by means of inhibition kinetics and in silico molecular modelling and docking. Moreover, to have a better understanding of the behaviour of these compounds with isoenzymes A1 and P1, we brought into context an in silico comparative approach for the proteins under study.
Kinetics of hGSTP1-1 inhibition by selected inhibitors
From the most potent inhibitors, we selected for enzyme inhibition kinetics those structures exhibiting distinctive chemical differences: a ketoxime (11), an aromatic N-acyl hydrazone (13) and an aliphatic N-acyl hydrazone (15) . When using CDNB as a variable substrate, all compounds displayed purely competitive inhibition kinetics on the basis of the linearity observed for both the double-reciprocal Lineweaver-Burk graphs (Figures 2A and S3a,b) and their respective secondary derivatives (Figures 2B and S3d,e) (26, 27) , at various steady inhibitor concentrations. This behaviour suggests that each of the inhibitors competes with CDNB for the same binding site of the respective allozyme: calculated inhibition constants K i(13/A) = 63.6 AE 3.0 lM (from Figure  S3d ), K i(15/B) = 198.6 AE 14.3 lM (from Figure S3e ) and K i(11/C) = 16.5 AE 2.7 lM (from Figure 2B ). Predictably, with GSH as a variable substrate, a mixed inhibition kinetics was observed, manifested by the lines of the double-reciprocal Lineweaver-Burk graph of initial velocities versus [GSH], at various steady inhibitor concentrations (i.e. compound 11), intersecting left of the reciprocal velocity axis ( Figure S4a ) (26, 27) . Furthermore, the linear correlation of the respective secondary derivative, depicting slope versus [inhibitor] (Figure S4b) , is supportive of a purely mixed type of inhibition (26, 27 ). This equilibrium model predicts that the inhibitor binds to both the free enzyme and the enzyme-GSH complex, without product formation (26, 27) , interacting at a site other than the GSH-binding site, that being partly the catalytic CDNB-binding site, as shown earlier (Figure 2A,B) . Interestingly, the same kinetic modality (e.g. purely competitive) had been observed earlier with 13 and hGSTA1-1, displaying, nonetheless, a substantially higher inhibitory potency (%167-fold), K i(13) = 0.38 AE 0.05 lM (7) as compared to 63.6 AE 3.0 lM with hGSTP1-1. On the other hand, the potency of compound 15, which was shown earlier to have a different inhibition modality with hGSTA1-1 (mixed hyperbolic) (7), is % 113-fold higher with hGSTA1-1, com- pared with hGSTP1-1, K i(15) 1.75 (7) versus 198.6 lM, respectively. Regardless of the different inhibition modality observed, both 13 and 15 are significantly weaker with the P1-1 isoenzyme, compared to A1-1. Taking into consideration the earlier discussion on the inhibition potency and the findings from the kinetics study, one can conclude that the compounds are directed to the H-site of the enzyme but with a varying selectivity for the particular isoenzyme, A1-1 and P1-1. Molecular modelling, docking and structural comparison studies may clarify certain aspects of this behaviour.
Molecular modelling and docking: in silico study of the selected inhibitors with hGSTA1-1 and hGSTP1-1 allozymes Three allelic variants of hGSTP1-1 (variant A PDB code 11GS, variant B PDB code 1PGT), containing an Ile104-Val or Ala113Val substitution or a combination of both, have been studied for in silico binding together with hGSTA1-1 (PDB code 1GSE) and showed different interaction parameters.
In regard to the differences between hGSTA1-1 and hGSTP1-1, it is apparent that the binding site of the former is much wider due to the shift of the C-terminal eleven amino acid residues (res 210-221 in hGSTA1 forming an a-helix, whereas res 201-207 in hGSTP1-1 forming a closed loop) (Figure 3 ). Although the binding site of hGSTP1-1 remains essentially the same from three sides, on the fourth (upper) side, the flexible C-terminal structure in hGSTP1-1 diminishes the binding site volume. Hence, compounds bound in hGSTP1-1 have to occupy a more restricted site, reducing possible modes of binding and affecting interactions (Figures 4 and S5 ). This is in agreement with the findings from the screening experiments (Table 1 ) and the earlier discussion (cf. % inhibition with hGSTA1-1 versus hGSTP1-1).
As to the hGSTP1-1 allozymes, the in silico binding results show that the mutation between the allozymes A, B and C of the amino acid side chain at residue position 104 is ligand dependent. Indeed, in accord with the available crystal structures of hGSTP1*A, hGSTP1*B and hGSTP1*C (28, 29) , position 104 is localized in the H-site of hGSTP1-1 and can affect enzyme activity in several ways dependent on the ligand (30) . The Ile104Val mutation affects the shape of the active site ( Figure 4B ) because Val104 occupies a smaller volume than Ile104, allowing the accommodation of larger ligands (28) . Also, residue 104 is close to the functional residue Tyr108, important in the catalytic mechanism of hGSTP1-1 by stabilizing the intermediate complex (31, 32) . In addition, mutation Ile104-Val has shown to alter the hydrophobicity/hydrophilicity status of the H-site of hGSTP1-1 by influencing the number of active-site water molecules that can interact during substrate binding and/or product release (32, 33) . These factors explain, in part at least, the selectivity of the compounds between hGSTA1-1 and hGSTP1-1 isoenzymes as well as between the hGSTP1-1 allozymes. Benzophenone analogues containing a hydrophobic moiety (e.g. phenyl ring) at position 5 are shown to optimally bind differently in hGSTA1-1 ( Figure 4B , ligands in blue) and in hGSTP1-1 ( Figure 4B , ligands in green for allozyme A and in red for allozymes B and C), the former isoenzyme not exposing the hydrophobic group to solvent, while the latter with a more open binding site having larger exposure to solvent. There are also differences in binding between hGSTP1-1 allozymes A and B,C, with A having ligands bound deeper in the pocket ( Figure S6 , green ligands) with reduced exposure of the ligand's hydrophobic groups, compared to B and C ( Figure S6, red ligands) . This is in agreement with the observation that all aryl-substituted compounds (6, 12, 13) show a stronger inhibition with hGSTP1-1A than the hGSTP1-1B,C allozymes (Table 1) . However, the diaryl-substituted 7 fails to bind effectively to any of the three hGSTP1-1 allozymes, due to the size and character (hydrophobic) of the substituting groups in the restricted polar binding site volume. Interestingly, the derivatization of the benzophenone carbonyl group (ketoximes 10-12, Figure S7a ) and N-acyl hydrazones (13-15, Figure S7b) enhances the inhibition potency towards the allozymes (Table 1) , possibly due to the formation of at least one hydrogen bond and reorientation of the compound in the binding pocket. This behaviour probably indicates an alternative (flipped) orientation in the enzyme-binding site. Furthermore, from the in silico study, it is apparent that the mode of binding to the P1-1 allozymes changes when compounds become amphipathic with the introduction of a bromine atom at position 5 (6 versus 8, Figure S8a ; 11 versus 12, Figure S8b ) but not at both positions 5 and 5 0 (7 and 9). This is in line with the observed differences in inhibition potency against the hGSTP1-1 allozymes (Table 1) .
Conclusion
(i) There is no uniform binding mode of the compounds in hGSTA1-1-and hGSTP1-1-binding sites but rather specific modes related to their substitution (i.e. phenyl or bromine groups) or carbonyl-derivatization pattern; (ii) disubstituted benzophenones (at positions 5 and 5 0 ) lose almost entirely their inhibition potency towards hGSTP1-1, compared to a fairly strong inhibitory potency towards hGSTA1-1, thus displaying isoenzyme specificity (A1-1 versus P1-1); (iii) monosubstituted benzophenones (at position 5) lose entirely their inhibition potency towards certain hGSTP1-1 allozymes and retain it towards others, thus displaying remarkable absolute allozyme specificity (P1-1A versus P1-1B versus P1-1C); and (iv) the derivatization on the carbonyl carbon for obtaining ketoximes and N-acyl hydrazones enhances their inhibition potency towards hGSTP1-1.
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